Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
The upcoming cancer meeting shows Roche and Bristol trying to catch up with Merck & Co, with some read-across to biotech.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.